• The combination of lamivudine and tenofovir is also sometimes used along with other medications to treat healthcare workers or other individuals exposed to HIV infection after accidental contact with HIV-contaminated blood, tissues, or other body fluids. (medlineplus.gov)
  • However, in these reports, the main infection genotype is D. Furthermore, if lamivudine improves survival, prognostic factors fof fulminant hepatitis B may differ from those reported previously. (elsevierpure.com)
  • The aim of this study was to clarify the prognostic factors and the efficacy of lamivudine for fulminant hepatitis B in Japan, where the main infection genotype is B. Methods: This study was a retrospective cohort study. (elsevierpure.com)
  • We selected 37 consecutive patients with falminant hepatitis due to acute hepatitis B virus infection. (elsevierpure.com)
  • Conclusion: This study suggests the efficacy of lamivudine for fulminant hepatitis B in the area where the main infection genotype is B. We consider that lamivudine is worth administering to patients with fulminant hepatitis B. (elsevierpure.com)
  • Lamivudine is a nucleoside analogue and reverse transcriptase inhibitor used in the therapy of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. (nih.gov)
  • Lamivudine is indicated for the treatment of HBV infection as a single agent and for HIV infection in combination with other HIV medications. (nih.gov)
  • For HIV infection, lamivudine is available as 150 and 300 mg tablets and as oral solutions under the trade name Epivir. (nih.gov)
  • The recommended dose of lamivudine for HIV infection in adults is 150 mg twice daily or 300 mg once daily. (nih.gov)
  • For HBV infection the recommended dose of lamivudine in adults is 100 mg orally once daily, the drug being available in this dose under the trade name Epivir-HBV. (nih.gov)
  • Lamivudine was approved by the FDA for HIV infection in 1995 and for HBV infection in 1998. (nih.gov)
  • Lamivudine is a rare cause of liver test abnormalities or clinically apparent liver injury in patients with HIV infection without hepatitis B. Although several instances of lactic acidosis with hepatic steatosis and liver failure have been reported in patients receiving lamivudine, in all instances other nucleoside analogues more clearly associated with mitochondrial injury [didanosine, stavudine, zalcitrabine, zidovudine] were also being taken. (nih.gov)
  • Lamivudine (Epivir) is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. (wikipedia.org)
  • Lamivudine (Epivir HBV) is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. (wikipedia.org)
  • The prevention of recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) with hepatitis B immunoglobulin (HBIG) is expensive and requires indefinite parenteral administration. (elsevierpure.com)
  • The aim of this study is to determine the efficacy of lamivudine in the prevention of recurrent HBV infection after a course of HBIG in patients who were hepatitis B surface antigen (HBsAg) positive and hepatitis Be antigen (HBeAg) negative before OLT. (elsevierpure.com)
  • These results suggest that lamivudine administered after a posttransplantation course of HBIG can effectively prevent the recurrence of HBV infection in patients who are HBsAg positive and HBeAg negative before OLT. (elsevierpure.com)
  • Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (nih.gov)
  • The study enrolled 35 patients with controlled HIV infection (mean baseline HIV RNA serum level of 2.88 log(10) copies/mL by Roche Amplicor Monitor PCR) who were receiving lamivudine 150 mg twice daily as part of their combination anti-HIV treatment regimen for a median of 42.3 months prior to enrollment. (gilead.com)
  • If you have hepatitis B virus infection and take tenofovir but then stop taking it, your hepatitis B could flare up and become worse. (healthline.com)
  • Tenofovir oral tablet is approved to treat HIV infection and chronic hepatitis B virus infection. (healthline.com)
  • chronic hepatitis B virus infection. (healthline.com)
  • Tenofovir works in the same way for both HIV infection and chronic hepatitis B virus infections. (healthline.com)
  • Worsening hepatitis B virus infection. (healthline.com)
  • DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg), in adults with HIV-1 infection who demonstrated virological suppression for at least six months on a stable antiretroviral treatment regimen. (merck.com)
  • Lamivudine Teva is used to treat adult patients who have chronic (long term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus). (europa.eu)
  • Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. (cdc.gov)
  • Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States . (cdc.gov)
  • and persons with a history of hepatitis C virus infection. (cdc.gov)
  • Persons with chronic hepatitis B virus (HBV) infection are at increased risk for liver cancer and cirrhosis and are 70%-85% more likely to die prematurely than the general population ( 1 - 4 ). (cdc.gov)
  • To provide a framework for reaching the World Health Organization's viral hepatitis elimination goals, the Viral Hepatitis National Strategic Plan for the United States calls for an increase in the proportion of persons with HBV infection who are aware of their infection from 32% (2013-2016) to 90% by 2030 ( 12 , 13 ). (cdc.gov)
  • The three main serologic markers used to determine HBV infection status are hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) ( Table 1 ). (cdc.gov)
  • It is used to treat people with chronic hepatitis B infection and evidence of hepatitis B virus replication (reproduction). (medbroadcast.com)
  • ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted Marketing Authorisation for Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. (gsk.com)
  • Dovato (dolutegravir 50 mg/ lamivudine 300 mg tablets) is authorised in the EU for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. (gsk.com)
  • In the US the Food and Drug Administration (FDA) authorised Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. (gsk.com)
  • Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin's Lymphoma) are limited, as well as prophylactic antiviral therapy for B-NHL patients with HBV infection who are receiving anticancer chemotherapy. (scirp.org)
  • It has also been proposed that hepatitis B virus (HBV) may be an etiologic agent of Non-Hodgkin's Lymphoma (NHL) [15] - [17] , but relatively few studies have investigated the association between HBV infection and B-NHL. (scirp.org)
  • The combination of lamivudine and zidovudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. (epnet.com)
  • Lamivudine and zidovudine controls HIV infection but does not cure it. (epnet.com)
  • Adefovir dipivoxil in chronic hepatitis B infection. (wikigenes.org)
  • LONDON, Aug. 25, 2014 /PRNewswire-HISPANIC PR WIRE/ - On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq ® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. (hispanicprwire.com)
  • More than 400 million people worldwide have chronic hepatitis B, which is caused by infection with the hepatitis B virus (HBV), and between one quarter and one third of these individuals are expected to develop progressive liver disease, such as cirrhosis and liver cancer. (gilead.com)
  • This type of short infection is known as an "acute" case of hepatitis B. About 10% of people infected with the hepatitis B virus develop a chronic, life-long infection. (adam.com)
  • Anyone who has chronic hepatitis B is also susceptible to infection with another strain of viral hepatitis known as hepatitis D (formerly called delta virus). (adam.com)
  • To assess the safety of anti-tumor necrosis factor (TNF)-alpha therapy in patients with rheumatic disease and chronic Hepatitis B virus (HBV) infection. (koreamed.org)
  • 11). ᄋksuzoglu B., Kilickap S., Yalcin S. Reactivation of hepatitis B virus infection in pancreatic cancer: a case report. (koreamed.org)
  • Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection. (koreamed.org)
  • The global burden of Hepatitis B virus (HBV) and HIV co-infection is enormous. (biomedcentral.com)
  • Baseline and on-treatment ALT may be a useful non-invasive predictor of Hepatitis B viremia in resource-constrained countries in sub-Saharan Africa where infection is endemic and viral load tests are not widely available. (biomedcentral.com)
  • Hepatitis C virus infection is the most frequent cause of chronic liver disease and the most common indication for liver transplantation. (aafp.org)
  • therefore, patients with hepatitis C infection should abstain from alcohol use. (aafp.org)
  • The term "chronic liver disease" encompasses a large number of conditions having different etiologies and existing on a continuum between hepatitis infection and cirrhosis. (aafp.org)
  • Hepatitis C is a common parenterally acquired infection that affects an estimated 4 million persons in the United States. (aafp.org)
  • 2 From 75 to 80 percent of persons with hepatitis C virus infection develop chronic hepatitis (diagnosed by the presence of persistently elevated liver injury test results for more than six months), and more than 25 percent develop cirrhosis within 30 to 40 years. (aafp.org)
  • 2 Hepatitis C virus infection is the leading cause of chronic liver disease and the reason for 30 to 35 percent of liver transplantations. (aafp.org)
  • 3 - 5 Thus far, treatments for hepatitis C virus infection have been somewhat disappointing, with the best response rates to interferon and ribavirin therapy reported at 40 percent. (aafp.org)
  • Many patients with hepatitis B virus infection fail standard therapy. (aafp.org)
  • Alcohol abuse and hepatitis C virus infection frequently coexist in patients with chronic liver disease. (aafp.org)
  • Investigators in one study 12 found that the effect of alcohol in patients with hepatitis C virus infection is not merely additive but synergistic, and that even moderate use of alcohol can hasten the development of cirrhosis. (aafp.org)
  • Aims Longstanding liver inflammation leads to hepatic regeneration and fibrosis, which subsequently progresses to cirrhosis in some patients with chronic hepatitis B virus (HBV) infection. (bmj.com)
  • The primary treatment goals for patients with hepatitis B (HBV) infection are to prevent progression of the disease, particularly to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). (medscape.com)
  • Newly acquired symptomatic hepatitis B virus (HBV) infection. (cdc.gov)
  • Newly acquired symptomatic hepatitis C virus (HCV) infection. (cdc.gov)
  • These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic hepatitis C infection. (bvsalud.org)
  • They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 20. (bvsalud.org)
  • These are the first World Health Organization (WHO) guidelines for the prevention, care and treatment of persons living with chronic hepatitis B (CHB) infection, and complement similar recently published guidance by WHO on the prevention, care and treatment of infection due to the hepatitis C virus (HCV). (bvsalud.org)
  • Trizivir (abacavir sulfate, lamivudine, and zidovudine) is a type of antiviral medication called a reverse transcriptase inhibitor used to treat HIV , which causes the acquired immunodeficiency syndrome ( AIDS ). (rxlist.com)
  • Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIZIVIR (abacavir, lamivudine, and zidovudine). (rxlist.com)
  • Lamivudine is also available in multiple fixed combinations with other antiretroviral agents such as zidovudine, abacavir, tenofovir, efavirenz, nevirapine, dolutegravir and others. (nih.gov)
  • Do not prescribe lamivudine/zidovudine, abacavir/lamivudine, or abacavir/lamivudine/zidovudine to patients taking emtricitabine. (wikipedia.org)
  • There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil and abacavir as well as with tenofovir disoproxil and didanosine as a once-daily regimen. (who.int)
  • 1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. (hispanicprwire.com)
  • a bioequivalence study of the fixed-dose combination of abacavir, dolutegravir and lamivudine when taken as a single pill compared to the administration of dolutegravir and abacavir/lamivudine as separate pills. (hispanicprwire.com)
  • 50 copies/mL) in the dolutegravir and abacavir/lamivudine arm (the separate components of Triumeq) than in the Atripla ®+ (efavirenz, emtricitabine and tenofovir) arm, the most commonly used single-pill regimen. (hispanicprwire.com)
  • Akima T, Tamano M, Yamagishi H, Kubota K, Fujimori T, Hiraishi H. Surgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil. (wjgnet.com)
  • To perform a cost-effectiveness evaluation from the perspective of the Brazilian National Health System of alternatives strategies (i.e., conventional interferon , pegylated interferon , and lamivudine ) for the treatment of patients with chronic hepatitis B who present elevated aminotransferase levels and no evidence of cirrhosis at the beginning of treatment . (bvsalud.org)
  • In the sensitivity analysis , the ICER was more sensitive to variation in the probability of transition from chronic hepatitis B to compensated cirrhosis , discount rate, and medicine prices . (bvsalud.org)
  • For patients with chronic hepatitis B with elevated aminotransferase levels in the pretreatment and no cirrhosis who were HBeAg positive, pegylated interferon (48 weeks) provided more life -years gained when compared to conventional interferon (24 weeks), and the ICER surpasses the country's buying power , which makes conventional interferon the chosen alternative. (bvsalud.org)
  • Having chronic hepatitis B increases your chance of permanent liver damage, including cirrhosis (scarring of the liver) and liver cancer. (adam.com)
  • Being infected with both hepatitis B and D raises the risk of developing cirrhosis or liver cancer. (adam.com)
  • Approximately 400 million individuals are infected with hepatitis B virus (HBV) globally [ 1 , 2 ] and 1 million patients die annually due to HBV-associated complications, such as liver cirrhosis and hepatocellular carcinoma [ 3 , 4 ]. (hindawi.com)
  • Worldwide, hepatitis B is another major cause of cirrhosis and hepatocellular carcinoma. (aafp.org)
  • Other recognized categories of chronic liver disease include conditions induced by toxins or drugs (e.g., alcohol) and autoimmune chronic liver diseases such as primary sclerosing cholangitis, primary biliary cirrhosis and autoimmune hepatitis. (aafp.org)
  • 8 Although each form of liver disease has a distinct natural history, most forms progress slowly from hepatitis to cirrhosis, often over 20 to 40 years. (aafp.org)
  • Hence, it is imperative to prevent further exacerbation of the disease and to optimize the length of time between hepatitis and the development of cirrhosis. (aafp.org)
  • Alcohol consumption has been associated with alcoholic hepatitis, fatty infiltration of the liver, accelerated progression of liver disease, a higher frequency of cirrhosis, a higher incidence of hepatocellular carcinoma, and death. (aafp.org)
  • Patients with acute or chronic hepatitis without cirrhosis have no dietary restrictions. (medscape.com)
  • About 20% of people with chronic hepatitis B develop cirrhosis or liver cancer and may die prematurely. (msdmanuals.com)
  • Some people who have chronic hepatitis B also have chronic hepatitis D. If untreated, the combination causes cirrhosis in up to 70% of affected people. (msdmanuals.com)
  • It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. (wikipedia.org)
  • A Markov model was developed for chronic hepatitis B ( hepatitis B antigen e [ HBeAg ] positive and negative) with 40 years' time horizon. (bvsalud.org)
  • Between February 2003 and December 2004, 83 (9.3%) out of 890 immigrants tested positive for hepatitis B surface antigen. (who.int)
  • The placebo-controlled studies included patients with compensated liver function and either "e" antigen-positive (HBeAg-positive) or "e" antigen-negative (HBeAg-negative, or precore mutant) chronic hepatitis B. The 48-week results from these two pivotal studies were published in the February 27 edition of the New England Journal of Medicine. (gilead.com)
  • [ 5 ] In addition, immunoglobulin and vaccination should be administered to newborns born to women positive for hepatitis B surface antigen (HBsAg). (medscape.com)
  • Antibody to hepatitis B core antigen. (cdc.gov)
  • Hepatitis B e antigen. (cdc.gov)
  • Hepatitis B surface antigen. (cdc.gov)
  • Hence, hepatitis B surface antigen seroclearance rarely occurs during NA treatment. (medscape.com)
  • Patients who are infected with HIV and HCV and are on both interferon and lamivudine can experience liver damage. (wikipedia.org)
  • Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. (bvsalud.org)
  • For HBeAg negative patients , it was observed that interferon (48 weeks) compared with long-term lamivudine presented an increase of 0.45 discounted life -years gained and ICER of US$15,766.90 per life -year gained. (bvsalud.org)
  • Cost - effectiveness acceptability curve for HBeAg positive (pegylated interferon vs. conventional interferon ) and negative (conventional interferon vs. lamivudine ) showed that conventional interferon was cost -effective until three times the gross domestic product per capita. (bvsalud.org)
  • For HBeAg negative patients , conventional interferon (48 weeks) compared to lamivudine provided more life -years gained at a favorable ICER. (bvsalud.org)
  • Intron A is the brand name of a medicine called interferon alpha which is used in the treatment of Chronic Active Hepatitis B and Hepatitis C. Other medicine used in Hepatitis B is lamivudin 100 mg. (ndtv.com)
  • A characterization of ALT flares observed in hepatitis B (HBV) treatment with the investigational interferon Lambda vs. alfa interferon, reflecting differing profiles for the two compounds. (aol.com)
  • The reported response rate to interferon is only 40 percent, and the response rate to second-line treatment using orally administered lamivudine is only about 30 percent. (aafp.org)
  • Eighty-five per cent (680/796) of patients were treated with antiviral agents such as interferon alpha and/or lamivudine. (bmj.com)
  • Our study underscores the potential of migratory flow to introduce genotype non-D hepatitis B virus into our country. (who.int)
  • Genotype E immigrants and in patients affected by ac- is found in sub-Saharan Africa and geno- tive chronic hepatitis HBV-related infec- type F in South and Central America. (who.int)
  • New insights into the hepatitis E virus genotype 3 phylodynamics and evolutionary history. (cdc.gov)
  • New Phase 2 data on an investigational triple direct-acting antiviral (DAA) regimen of daclatasvir (NS5A replication complex inhibitor), asunaprevir (NS3 protease inhibitor) and BMS-791325 (NS5B non-nucleotide polymerase inhibitor) in patients with hepatitis C (HCV) genotypes 1a and 1b. (aol.com)
  • Patients with hepatitis B disease and fulminant hepatic failure should be hospitalized in the intensive care unit (ICU) and be considered as liver transplant candidates in the event that they do not recover. (medscape.com)
  • HBV, hepatitis B virus. (cdc.gov)
  • Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. (cdc.gov)
  • If you stop taking lamivudine and tenofovir even for a short time, or if you skip doses, the virus may become resistant to medications and may be harder to treat. (medlineplus.gov)
  • Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. (e-cmh.org)
  • Patients with chronic hepatitis B (CHB) and continuously high levels of serum hepatitis B virus (HBV) DNA have an increased risk for progression of hepatic fibrosis and development of hepatocellular carcinoma (HCC) [ 1 , 2 ]. (e-cmh.org)
  • Blood and any body fluid visibly contaminated with blood should be considered capable of transmitting hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). (medscape.com)
  • Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. (wikipedia.org)
  • Long-term use of lamivudine leads to emergence of a resistant hepatitis B virus (YMDD) mutant. (wikipedia.org)
  • Long-term use of lamivudine can trigger a resistant hepatitis B virus (YMDD) mutant. (wikipedia.org)
  • It can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B virus. (wikipedia.org)
  • BOSTON, Oct 28, 2003 (BUSINESS WIRE) -- Gilead Sciences (Nasdaq:GILD) today announced that treatment with its once-daily, oral antiviral agent Hepsera(R) (adefovir dipivoxil 10 mg) was associated with sustained reductions in levels of hepatitis B virus (HBV) DNA through 144 weeks (approximately three years) among patients chronically infected with lamivudine-resistant HBV and co-infected with HIV. (gilead.com)
  • Hepsera, the first nucleotide analogue for chronic hepatitis B, is administered as a once-daily 10 mg tablet and works by blocking HBV DNA polymerase, an enzyme involved in the replication of the virus in the body. (gilead.com)
  • It's also a hepatitis B virus reverse transcriptase inhibitor (RTI). (healthline.com)
  • Doravirine, lamivudine, and tenofovir are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. (cigna.com)
  • Doravirine, lamivudine, and tenofovir is a combination medicine used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). (cigna.com)
  • Because the hepatitis B virus can become resistant to Lamivudine Teva, the doctor should only consider prescribing Lamivudine Teva if other treatments that are less likely to lead to resistance cannot be used. (europa.eu)
  • If the hepatitis B virus can still be found in the blood after six months of treatment, the doctor should consider changing treatment to reduce the risk of resistance. (europa.eu)
  • Patients infected with a virus that has the 'YMDD mutation' (a change in the virus's DNA that is often found after treatment with lamivudine) should take Lamivudine Teva in combination with another medicine against hepatitis B. For more information, please see the summary of product characteristics (also part of the EPAR). (europa.eu)
  • Lamivudine stops the virus making DNA and prevents it from multiplying and spreading. (europa.eu)
  • It works by stopping the hepatitis B virus from reproducing. (medbroadcast.com)
  • lamivudine can decrease the amount of hepatitis B virus in the body and may reduce the damage done to the liver by the hepatitis B virus. (medbroadcast.com)
  • 1 Zhang F, Wang G.. A review of non-nucleoside anti-hepatitis B virus agents. (thieme-connect.de)
  • Efficacy and safety of lamivudine or telbivudine in preventing mother-to-child transmission of hepatitis B virus: a real-world study. (thieme-connect.de)
  • Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. (thieme-connect.de)
  • Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. (thieme-connect.de)
  • B is associated with faster hepatitis Be are chronic carriers of the virus [ 1,2 ]. (who.int)
  • Objective To assess the impact of various antiretroviral/antiviral regimens in pregnant women living with HIV or hepatitis B virus (HBV). (bmj.com)
  • Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. (wikigenes.org)
  • Chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections are major causes of liver disease and hepatocellular carcinoma worldwide. (mdpi.com)
  • In July 2002, Gilead initiated an early access program to provide Hepsera to chronic hepatitis B patients with lamivudine-resistant virus. (gilead.com)
  • Hepatitis is a serious inflammation of the liver, usually due to a virus. (adam.com)
  • You can also get hepatitis A by having sex with someone who has the virus. (adam.com)
  • Unlike other forms of viral hepatitis, the virus does not stay in your body once you recover. (adam.com)
  • Most people who become infected with hepatitis B get rid of the virus within 6 months. (adam.com)
  • Hepatitis D virus can only infect cells if the hepatitis B virus (HBV) is present. (adam.com)
  • There is no vaccine for hepatitis E. The only way to prevent the disease is to reduce the risk of exposure to the virus. (adam.com)
  • Having unprotected sex with someone who is infected can also pass on the hepatitis B virus (it is rarer for hepatitis C to be transmitted through sexual activity). (adam.com)
  • Many viruses can cause hepatitis, including herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and others. (adam.com)
  • Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. (koreamed.org)
  • Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepato-cellular carcinoma. (koreamed.org)
  • Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. (koreamed.org)
  • Because superinfection with hepatitis A or B virus can lead to liver failure, vaccination is recommended. (aafp.org)
  • It is widely believed that alcohol and the hepatitis C virus act together to promote the development and progression of liver damage. (aafp.org)
  • The mechanism for the synergistic effect of alcohol and hepatitis C virus is not fully understood, but it has been attributed to the effects of alcohol on viral replication and the immune system, hepatic iron content and hepatic regeneration. (aafp.org)
  • Chronic hepatitis B is inflammation of the liver that is caused by the hepatitis B virus and that has lasted more than 6 months. (msdmanuals.com)
  • Hepatitis B, Acute Acute hepatitis B is inflammation of the liver that is caused by the hepatitis B virus and that lasts from a few weeks up to 6 months. (msdmanuals.com)
  • If the level of hepatitis B virus (viral load) is high in pregnant women, they are often given antiviral drugs during the last trimester of pregnancy to prevent transmission of the virus from mother to child. (msdmanuals.com)
  • Antibody to hepatitis C virus. (cdc.gov)
  • Hepatitis B virus deoxyribonucleic acid. (cdc.gov)
  • Hepatitis C virus. (cdc.gov)
  • Hepatitis C virus ribonucleic acid. (cdc.gov)
  • Hepatitis D virus. (cdc.gov)
  • Lamivudine is currently used in many HAART regimens but is now rarely used to treat hepatitis B because of a high rate of antiviral resistance when it is used as monotherapy as well as the availability of more potent agents with a higher barrier to resistance. (nih.gov)
  • Severe adverse events occur largely when it is withdrawn in patients with chronic hepatitis B or with the development of antiviral resistance. (nih.gov)
  • These elevations appear to be due to a transient flare in the underlying chronic hepatitis B and occur in three situations during and after therapy: upon initiation of therapy (treatment flares), upon development of antiviral resistance (breakthrough flares), and shortly after stopping therapy (withdrawal flares). (nih.gov)
  • The widespread use of antiviral agents with low genetic barriers to resistance, such as lamivudine (LAM), adefovir (ADV), telbivudine (LdT), and clevudine (approved in South Korea), as initial treatment is one of the main causes of the high prevalence of genotypic resistance to NUCs among patients with CHB in Asian countries [ 10 ]. (e-cmh.org)
  • The active substance in Lamivudine Teva, lamivudine, is an antiviral agent belonging to the class of the nucleoside analogues. (europa.eu)
  • Entecavir maybe the better antiviral drugs than Lamivudine, and antiviral therapy is maintained more than 6 months that maybe the optimal duration of prophylactic antiviral therapy. (scirp.org)
  • Not everyone with chronic hepatitis B needs treatment, but if chronic hepatitis B is damaging the liver (causing inflammation or scarring), an antiviral drug is started. (msdmanuals.com)
  • The Committee recommended the addition to the WHO Model List of Essential Medicines of various direct-acting antiviral medicines, including fixed-dose combinations for the treatment of chronic hepatitis C, based on evidence supporting their substantial therapeutic benefit, satisfactory safety profile, and shorter treatment duration. (who.int)
  • Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B? (hivandhepatitis.com)
  • In addition to these compounds, the Company's medicine BARACLUDE ® (entecavir) is approved for the treatment of chronic hepatitis B (CHB) in adults with evidence of active viral replication and either evidence of persistent elevations in aminotransferases (ALT or AST), or histologically active disease. (aol.com)
  • These agents are classified according to their chemical structures: the three nucleoside analogues include lamivudine, telbivudine and entecavir, whereas the two nucleotide analogues include adefovir dipivoxil, tenofovir disoproxil fumarate (TDF), [ 2 ] and the newly approved tenofovir alafenamide (TAF). (medscape.com)
  • In hepatitis B, lamivudine resistance was first described in the YMDD (tyrosine-methionine-aspartate-aspartate) locus of the HBV reverse transcriptase gene. (wikipedia.org)
  • Lamivudine-resistant HBV (confirmed "YMDD" mutation) was detected in patients a median of 21.3 months prior to initiating treatment with Hepsera. (gilead.com)
  • Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. (nih.gov)
  • Clinical and laboratory evidence of exacerbations of hepatitis has been observed after discontinuation of treatment with Hepsera. (gilead.com)
  • tell your doctor and pharmacist if you are allergic to lamivudine, tenofovir, any other medications, or any of the ingredients in lamivudine and tenofovir tablets. (medlineplus.gov)
  • For patients with difficulty swallowing tablets, other lamivudine formulations, e.g. oral solution, may be available. (who.int)
  • Dovato (dolutegravir 50 mg/ lamivudine 300 mg tablets) was authorised by the US Food and Drug Administration in April 2019 [5] (please see US Prescribing Information including Box Warning), and further regulatory applications have been submitted worldwide. (gsk.com)
  • An exacerbation of hepatitis also typically occurs after development of lamivudine resistance, a few weeks or months after the initial appearance of the mutant HBV strain and rise in HBV DNA levels (Case 2). (nih.gov)
  • The COLATE study has suggested that there is no benefit to continuing lamivudine treatment in patients with lamivudine resistance. (wikipedia.org)
  • The development of resistance - which emerges in up to 90 percent of immunocompromised HBV-infected patients after four years of therapy with lamivudine - can lead to progression of chronic hepatitis B," said Dr. Benhamou. (gilead.com)
  • To date, the limitations of available hepatitis B drugs, such as poor tolerability and rapid development of viral resistance, have made them unsuitable or ineffective for many patients," said Professor Stephanos Hadziyannis, MD, Department of Medicine, Henry Dunant Hospital, Athens, Greece. (gilead.com)
  • Broad efficacy, good tolerability and a low risk of resistance make Hepsera an important advancement in the treatment of chronic hepatitis B. (gilead.com)
  • Hepsera also has been studied in patients who were treated with and developed resistance to lamivudine, including patients wait-listed for liver transplantation, post-liver transplantation patients and patients co-infected with HIV. (gilead.com)
  • Dolutegravir plus lamivudine continued to demonstrate a high genetic barrier to treatment-emergent resistance. (natap.org)
  • The percentage of individuals with protocol-defined confirmed virologic withdrawal (CVW) was 1.7% (12/716) in the dolutegravir plus lamivudine arm and 1.3% (9/717) in the dolutegravir plus TDF/FTC arm.1 None of these participants developed treatment-emergent resistance mutations. (natap.org)
  • Lamivudine is a nucleoside analogue capable of inhibiting HBV replication. (elsevierpure.com)
  • The safety results for dolutegravir and lamivudine seen in GEMINI 1 and 2 were consistent with the product labelling for dolutegravir and lamivudine. (gsk.com)
  • Four patients (1%) in both the dolutegravir and lamivudine, and the dolutegravir and TDF/FTC, study arms experienced drug-related serious adverse events, and 15 patients (2%) in the dolutegravir and lamivudine arm and 16 patients (2%) in the dolutegravir and TDF/FTC arm had adverse events that led to discontinuation. (gsk.com)
  • This treatment allows individuals to take a two-drug regimen in a single pill with dolutegravir at the core, building on the established potency and safety profiles of dolutegravir and lamivudine. (gsk.com)
  • Your doctor may test you to see if you have HBV before you begin your treatment with lamivudine and tenofovir. (medlineplus.gov)
  • Dive into the research topics of 'Lamivudine treatment improves the prognosis of fulminant hepatitis B'. Together they form a unique fingerprint. (elsevierpure.com)
  • Lamivudine treatment improves the prognosis of fulminant hepatitis B . Internal Medicine , 47 (14), 1293-1299. (elsevierpure.com)
  • Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV/AIDS. (wikipedia.org)
  • Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (nih.gov)
  • In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (gilead.com)
  • You may need to start treatment for hepatitis B again. (healthline.com)
  • Treatment with Lamivudine Teva should be initiated by a doctor who has experience in the management of chronic hepatitis B. The recommended dose of Lamivudine Teva is 100 mg once a day. (europa.eu)
  • For more information about treatment with Lamivudine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. (europa.eu)
  • HIV and Hepatitis.com is published by HIV and Hepatitis Treatment Advocates, Inc . (hivandhepatitis.com)
  • VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older. (nih.gov)
  • Recommended dose for the treatment of HIV-1 or chronic hepatitis B in adults and pediatric patients 12 years of age and older (35 kg or more): 300 mg once daily taken orally without regard to food. (nih.gov)
  • I want ask about Hepatitis B and Hepatitis C. Is there any satisfactory treatment for this? (ndtv.com)
  • The data we are presenting at the International Liver Congress demonstrate our continued advancement of research to address unmet medical needs, through the development of regimens for personalized hepatitis C treatment and increasing options to treat hepatitis B. (aol.com)
  • With extended treatment, mild to moderate, reversible, increases in serum creatinine were observed infrequently in patients with chronic hepatitis B and compensated liver disease treated with Hepsera for a median of 49 weeks and a maximum of 109 weeks. (gilead.com)
  • Changes in serum creatinine were observed very commonly in patients with pre- and post-liver transplantation with lamivudine-resistant hepatitis B and multiple risk factors for changes in renal function who were treated with Hepsera for up to 129 weeks, with a median time on treatment of 19 and 56 weeks, respectively. (gilead.com)
  • These studies evaluate a 2-drug regimen of dolutegravir plus lamivudine compared with a 3-drug regimen of dolutegravir plus TDF/FTC in HIV-1 infected, antiretroviral treatment-naïve adult participants with baseline HIV-1 viral loads between 1,000 and 500,000 c/mL. (natap.org)
  • The studies were designed to demonstrate the non-inferior efficacy at Week 48, as well as the safety and tolerability of once-daily dolutegravir plus lamivudine compared to once-daily dolutegravir plus the fixed-dose combination of TDF/FDC in HIV-1-infected, antiretroviral treatment-naïve adult participants. (natap.org)
  • Why do people with HIV delay hepatitis C treatment? (aidsmap.com)
  • One of the cases treated with lamivudine before anti-TNF-alpha therapy for chronic hepatitis B treatment. (koreamed.org)
  • In treatment experienced patients, elevated ALT (OR 4.8 CI 2.0 - 12.1) and male sex (OR 2.1, 95 % CI 1.0 - 4.2) were associated with Hepatitis B viremia. (biomedcentral.com)
  • An abnormal serum ALT was significantly associated with hepatitis B viremia in HBV and HIV co-infected patients irrespective of treatment status. (biomedcentral.com)
  • TANGO is a phase III, randomised, open-label, active-controlled, multicentre, parallel-group study comparing dolutegravir plus lamivudine once daily against continuation of a ≥3-drug tenofovir alafenamide (TAF)-based regimen over 48-weeks in HIV-1 infected, antiretroviral treatment-experienced, virally suppressed subjects. (gsk.com)
  • The development of oral anti-viral treatment with nucleos(t)ide analogues (NAs) has revolutionised the management of chronic hepatitis B (CHB) in the last two decades. (medscape.com)
  • In the United States, viral hepatitis usually appears as type A, B, or C. Two other types, D and E, are rare in the U.S. (adam.com)
  • Type A is the most common form of viral hepatitis. (adam.com)
  • It remains unclear, however, if the histological severity of chronic hepatitis B (CHB) may determine the development of hepatocellular carcinoma (HCC). (bmj.com)
  • Lamivudine is taken by mouth as a liquid or tablet. (wikipedia.org)
  • Each butterscotch-coloured, film-coated, capsule-shaped tablet, engraved 'GXCG5' on one side, contains 100 mg of lamivudine. (medbroadcast.com)
  • For these patients another formulation should be used, e.g. a tablet that can be given at a smaller dose or an oral solution of lamivudine. (who.int)
  • The GEMINI 1 & 2 phase III studies compared a 2DR of dolutegravir plus lamivudine to a 3-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (TDF/FTC). (gsk.com)
  • If appropriate, resumption of anti-hepatitis B therapy may be warranted. (nih.gov)
  • Lamivudine is phosphorylated intracellularly to the triphosphate which competes with the naturally occurring cytidine triphosphate for incorporation into the growing HIV or HBV DNA chain by the viral polymerase, thereby inhibiting polymerase (or reverse transcriptase) activity and causing chain termination. (nih.gov)
  • Lamivudine interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA. (europa.eu)
  • People with chronic hepatitis do not always have the symptoms of acute hepatitis. (adam.com)
  • Patients with acute hepatitis should be monitored with blood tests in order to document biochemical improvement (see Workup). (medscape.com)
  • Acute hepatitis B becomes chronic in about 40% of people being treated with hemodialysis and in up to 20% of people with a weakened immune system. (msdmanuals.com)
  • A better explanation of the data is that lamivudine continues to have a partial anti-viral effect even in the presence of the M184V mutation. (wikipedia.org)
  • Much less commonly, neuropathy can be caused by 3TC (lamivudine, and in Combivir, Kivexa and Trizivir) and T-20 (enfuvirtide, Fuzeon). (catie.ca)
  • What is the most important information I should know about doravirine, lamivudine, and tenofovir? (cigna.com)
  • Doravirine, lamivudine, and tenofovir may also be used for purposes not listed in this medication guide. (cigna.com)
  • What should I discuss with my healthcare provider before taking doravirine, lamivudine, and tenofovir? (cigna.com)
  • Some drugs should not be used together with doravirine, lamivudine, and tenofovir. (cigna.com)
  • You may be more likely to have a broken bone while using doravirine, lamivudine, and tenofovir. (cigna.com)
  • How should I take doravirine, lamivudine, and tenofovir? (cigna.com)
  • If you also take a medicine called rifabutin, you may need to take an extra dose of doravirine (Pifeltro) about 12 hours after you take the doravirine, lamivudine, and tenofovir combination (Delstrigo). (cigna.com)
  • Lamivudine is a very rare cause of clinically apparent drug induced liver injury, but is associated with flares of underlying hepatitis B during therapy or with abrupt withdrawal. (nih.gov)
  • Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? (thieme-connect.de)
  • We synthesise the best available evidence to inform choice of HIV and/or hepatitis B therapy for pregnant women. (bmj.com)
  • His hepatitis status was maintained stable after he initiated anti-TNF-alpha therapy. (koreamed.org)
  • Five of the cases started anti-TNF-alpha therapy without lamivudine. (koreamed.org)
  • Two of these five cases were received lamivudine during anti-TNF-alpha therapy due to elevation of HBV DNA titer without liver function test abnormality and then HBV DNA was normalized. (koreamed.org)
  • The recommended dose of lamivudine is 300 mg daily. (who.int)
  • It is recommended that lamivudine dose be modified in patients with reduced creatinine clearance as shown below. (who.int)
  • In patients with moderate to severe renal impairment, the terminal plasma half-life of lamivudine is increased due to decreased clearance, therefore the dose should be adjusted (see section 4.2). (who.int)
  • It cannot ask about our hepatitis B or what drugs we take, nor can it impose any caps on our medical expenses. (hepb.org)
  • I read in a book that a new drugs has been discovered by the name of Intron A injections which can cure hepatitis. (ndtv.com)
  • I had been prepared for a lifetime of taking these drugs and closely monitoring the hepatitis to try and prevent any liver damage. (hepb.org)
  • Are New Drugs for Hepatitis C Safe? (aidsmap.com)
  • [1] The data presented at IAS 2019 will evaluate the efficacy of dolutegravir plus lamivudine compared to the 3-drug regimen at the Week 96 secondary endpoint. (gsk.com)
  • Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. (wikipedia.org)
  • Study 460i is a single-center, open-label study of Hepsera in chronic hepatitis B patients with lamivudine-resistant HBV and co-infected with HIV. (gilead.com)
  • The approval of Hepsera by the European Commission comes less than a year after Gilead filed its Marketing Authorisation Application with the European authorities, demonstrating the important unmet medical need Hepsera will address for physicians and their patients with chronic hepatitis B," said John C. Martin, PhD, President and CEO, Gilead Sciences. (gilead.com)
  • The purpose of this study is to explore the predictive value of cytokine levels in the first trimester of pregnancy on abnormal liver function of pregnant women with hepatitis B in the third trimester of pregnancy. (thieme-connect.de)
  • The high expression level of cytokine IL-6 at 12 weeks of pregnancy has noteworthy predictive significance for the abnormal liver function of hepatitis B pregnant women in third trimester of pregnancy. (thieme-connect.de)
  • Information on HIV and hepatitis C transmission and prevention, including STIs and safer sex, harm reduction, pregnancy and infant feeding, and microbicides and vaccines. (catie.ca)